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ABSTRACT
We describe the case of an acromegalic subject, who was the first
patient ever treated with the GH receptor antagonist pegvisomant.
Furthermore, in this particular patient, progression in tumor size was
encountered during treatment with pegvisomant. The patient de-
scribed did benefit from cotreatment with pegvisomant and oct-
reotide, including decreased GH levels, normalization of serum in-
sulin-like growth factor I concentrations, and improvement of visual
field defects. (J Clin Endocrinol Metab 86: 478–481, 2001)
THIS 34-YR-OLD MALE patient was treated by trans-sphenoidal selective adenomectomy for a convex GH-
producing pituitary macroadenoma in February 1997. He
had, at that time, active acromegaly with fatigue, headaches,
excessive perspiration, and joint pains. Before surgery, a
single injection of 50 mg octreotide sc decreased the serum
GH concentration from 70 ng/mL to minimally 6 ng/mL
after 6 h. Serum PRL was normal, whereas secondary hy-
pothyroidism and hypogonadism were present. These were
subsequently treated by replacement therapy. The neuro-
surgical procedure was unsuccessful because 6 months after
operation the tumor still extended up to the optic chiasm,
although without signs or symptoms of compression of the
chiasm. Because of the extension close up to the optic chiasm,
it was decided not to treat him with radiotherapy. Because
of tumor size and persistent disease activity, he started treat-
ment with octreotide in sc dosages up to 200 mg three times
daily (t.i.d.). This did not result in normalization of his serum
total insulin-like growth factor I (IGF-I) concentrations (un-
treated IGF-I levels, 6230 nmol/L; age-adjusted upper nor-
mal level, ,50 nmol/L; nadir in serum total IGF-I levels
during treatment with octreotide 200 mg sc t.i.d., 170 nmol/
L). Therefore, it was concluded that this patient was only
partially sensitive to octreotide.
In April 1997, he received for the first time pegvisomant,
as he participated as the first patient in a dose-finding study
in our center. The pegvisomant dose administered was 0.3
mg/kg body weight (27.6 mg). A single sc administration of
the GH receptor (GHR) antagonist resulted in a decline in the
total serum IGF-I level on day 3 after the injection without
reaching normal levels (from 233 nmol/L to 211 nmol/L).
In July 1997, he was enrolled in a Phase 2b study on the
efficacy and safety of pegvisomant in the treatment of acro-
megaly. In this 6-week placebo-controlled study, he was
randomized to receive 80 mg pegvisomant sc once weekly.
A significant decrease in serum total IGF-I levels was ob-
served (from 305 mmol/L to 190 nmol/L), although the
result was still three times the upper age-adjusted normal
level (,50 nmol/L).
Because temporarily no study drug was available, he was
treated again with octreotide sc (200 mg sc t.i.d) between
October 1997 and February 1998. In this period, the nadir in
total serum IGF-I concentrations in the pegvisomant-free
period remained the same as before the first period of treat-
ment with the GHR antagonist (around 150 nmol/L; see
Table 1), indicating that he still was only partially sensitive
to octreotide treatment.
From March 1998 onward, however, he was treated again
with pegvisomant, without interruptions. In this period,
pegvisomant was administered daily by sc injections, instead
of weekly injections. A dose-responsive reduction in IGF-I
was observed as daily doses were gradually increased from
10 mg sc to the maximal allowed daily dose in this study of
40 mg (see Fig. 1), although the final serum IGF-I concen-
tration was still slightly above the upper limit of normal. This
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resulted in high pegvisomant concentrations (concentrations
around 50,000 ng/mL). Also, a very significant increase in
serum GH levels was observed (maximal serum GH con-
centration during pegvisomant therapy, ;260 ng/mL).
During September and October 1999, serum total IGF-I
concentrations started to increase again, while for the first
time bitemporal visual fields defects were found because of
a small, but significant, increase in tumor size, whereby the
suprasellar extension was increased to the extent that com-
pression of the chiasm was radiologically very likely (see
Table 1). These observations were accompanied by an un-
explained decrease in serum pegvisomant concentrations,
without a change in dose. The patient’s compliance was
considered to be optimal throughout the whole period of
observation, however (e.g. by the interpretation of drug-
accountability forms).
In November 1999, it was decided to start treatment with
octreotide, together with 40 mg sc pegvisomant once daily.
Therefore, 30 mg Sandostatin LAR therapy was initiated.
This resulted in a rapid normalization of serum total IGF-I
concentrations within 2 months (see Fig. 1), whereas the
abnormalities in the visual field completely resolved. Also,
no further increase in tumor size on magnetic resonance
imaging (MRI) was observed between July 1999 and March
2000. At the same time, a striking decrease in serum GH
concentrations was observed as well, down to levels com-
parable with concentrations before the start of pegvisomant
treatment. As least up to April 2000, serum IGF-I levels
remained well controlled with levels around 35 nmol/L.
Signs and symptoms of acromegaly were considerably im-
proved as well.
Discussion
The primary goal in the management of acromegaly is to
reverse the effects of GH hypersecretion and to decrease
tumor size as much as possible (1–3). The importance of
“normalizing” the GH/IGF-I axis has been demonstrated in
two long-term studies of surgery (4, 5) in which the mortality
rates of patients with acromegaly in whom disease control
was inadequate were not different than those of matched
controls, in contrast to the 2.4- to 4.8-fold greater mortality
in patients who had persistent disease. Therefore, tight con-
trol of the GH/IGF-I axis is now considered to be an achiev-
able and desired goal of therapy (6).
The reported efficacy data of the available long-acting
somatostatin analogs in reducing serum IGF-I levels in ac-
romegalic patients indicate that effective control of disease
activity can be achieved in two thirds of patients who are
sensitive to somatostatin analogs (7–12). This leaves at least
one third of the patients without an effective control of dis-
ease activity by medical intervention. To our knowledge,
there are no reports available that describe an increase in size
of a somatotropinoma during long-term treatment with so-
matostatin analogs.
The present case illustrates several important issues re-
garding the future use of GHR antagonists on a large scale
in the (near) future.
Pegvisomant
Pegvisomant is a genetically manipulated GH molecule
that disables functional dimerization of the two GHR mol-
ecules involved in signal transduction, due to a single mu-
tation at the site II of the GH molecule. Pegvisomant is
pegylated to increase serum half-life time and to reduce the
likelihood of antibody formation. Currently, the compound
is under investigation in the treatment of acromegaly (13–15).
Pegvisomant blocks GH action, instead of inhibiting GH
secretion as somatostatin analogs. This implies that during
pegvisomant therapy GH levels are not indicative for GH-
mediated action on IGF-I production. Although the unpe-
gylated GHR antagonist does have a higher affinity at site I
of the GH, compared with endogenous GH, one must con-
clude that the pegylation process has major influences on this
affinity, because in this particular patient pegvisomant con-
centrations of as high as 50,000 ng/mL were not able to block
GH action of GH concentrations more than 200-fold lower
(250 ng/mL), although serum IGF-I concentrations in our
patient nearly normalized when pegvisomant levels were
around 50,000 ng/mL. Strikingly, in the Phase II and III
studies, no clear-cut correlation between pegvisomant con-
centrations, GH levels, and efficacy data were observed (13–
15). In this particular patient, pegvisomant concentrations
TABLE 1. Serum total IGF-I and tumor volume in cubic centimeters during medical treatment of a 34-yr-old acromegalic patient with
octreotide alone, pegvisomant alone, and during coadministration with both compounds
Date Pegvisomant dose Octreotide dose Volume (cc) IGF-I (nmol/L) Comments
July 1997 80 mg weekly 2.5 216
October 1997 Octreotide 200 mg t.i.d. 2.9 162
March 1998 10 mg daily 152
May 1998 10 mg daily 4.3 145
June 1998 15 mg daily 127
August 1998 20 mg daily 101
October 1998 25 mg daily 140
November 1998 30 mg daily 125
February 1999 30 mg daily 4.9 80
June 1999 35 mg daily 85
July 1999 40 mg daily 102
September 1999 40 mg daily 5.4 122
October 1999 40 mg daily 103 Visual field defects
November 1999 40 mg daily 30 mg monthly (LAR) 82 Visual field defects
December 1999 40 mg daily 30 mg monthly (LAR) 35 Visual field defects
January 2000 40 mg daily 30 mg monthly (LAR) 37 Normalization of visual disturbances
March 2000 40 mg daily 30 mg monthly (LAR) 5.4 37
OCTREOTIDE AND PEGVISOMANT CO-TREATMENT 479
 at Medical Library Erasmus MC on November 28, 2006 jcem.endojournals.orgDownloaded from 
seem to be roughly correlated to the serum IGF-I response
throughout the course of therapy. An unexpected finding
was the 2-fold increase in serum pegvisomant concentra-
tions, which was observed within 1 month after the initiation
of octreotide treatment, while pegvisomant dosages were
unchanged (40 mg daily). The reasons for this are unclear.
GH concentrations
As has been reported before, pegvisomant induces an in-
crease in endogenous serum GH concentrations in acrome-
galic patients. Whether this dose-dependant increase in se-
rum GH concentrations reflects a reduction in receptor-
mediated GH clearance, an increase in production, or
modification of some other pathway remains unclear yet.
Studies on the effect of GHR blockade on the pharmacody-
namics of serum GH levels are currently being performed.
The important observation in the present case, however, is
that lowering serum GH concentrations by octreotide coad-
ministration results in a synergistic decrease in serum IGF-I
concentrations not achieved with octreotide or pegvisomant
administrated alone. This synergistic effect might be pre-
dicted, based on the mechanism of action of pegvisomant as
a competitive GHR antagonist. Lowering GH levels would,
therefore, make a given concentration of pegvisomant more
effective.
Tumor size
The present case describes the first patient in whom pro-
gression in tumor size was encountered during treatment
with pegvisomant. No data are yet available that indicate
whether or not the size of a GH-producing tumor is modified
by pegvisomant. It is, therefore, possible that some patients
with aggressive tumors will show an increase in tumor size
during long-term treatment with pegvisomant alone. There-
fore, patients treated with pegvisomant should receive rou-
tine MRI monitoring of tumor size at least until more data
become available. The aggressiveness of the tumor in this
particular patient might reflect a subgroup of patients in
whom a close follow-up of tumor size is mandatory with any
treatment. It is still unclear, however, whether the observed
increase in size of the tumor in this patient has been part of
the natural history of growth of this tumor, in addition to
growth secondary to the use of a GH antagonist. In this
patient, cotreatment with octreotide and pegvisomant did
result in an improvement in the visual field defects, whereas
no further increase in tumor size was observed in between
the last two MRI examinations 8 months apart. In this period,
cotreatment was applied in the last 4 months.
Conclusion
We describe a 34-yr-old male acromegalic patient in whom
a high dose of 40 mg pegvisomant (by sc daily injections) did
not completely normalized serum IGF-I concentrations. Fur-
thermore, he is the first patient in whom progression in
tumor size was encountered during treatment with pegvi-
somant, and finally he was the first patient who was suc-
cessfully treated with long-acting octreotide together with
pegvisomant. This cotreatment resulted in an adequate con-
trol of biochemical disease activity, as well as an improve-
ment of visual field defects and a further improvement in
signs and symptoms.
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